@sylrose68's second Wegovy dose experience, fact-checked

What did @sylrose68 actually say?

She's two doses into Wegovy at 0.25mg, and her honest take is that it hasn't done a single thing. "I don't feel like it's done a single thing," she says, and she's worried she's wasted £200 on a pen. She also correctly identifies that the starting dose is a four-week build-up phase, that appetite suppression shouldn't necessarily be expected yet, and that diet changes (less caffeine, alcohol, processed food) will matter alongside the medication. She mentions being pre-diabetic, mentions ADHD assessment, and pushes back on commenters who might suggest she use it for diabetes rather than weight loss.

That's a lot packed into one video. Some of it is genuinely accurate. Some of it needs more nuance. And one or two things she worries about are probably not worth worrying about.

Does the science back this up?

Yes, largely. The 0.25mg starting dose of semaglutide is not a therapeutic dose. It is a tolerability dose. The clinical evidence is consistent on this point.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) used a 16-week dose escalation schedule before participants reached the 2.4mg maintenance dose. Meaningful weight loss and appetite suppression in that trial were observed at higher doses, not at 0.25mg. At the lower end of the escalation, the pharmacodynamic effect on appetite-regulating GLP-1 receptors in the hypothalamus is simply not strong enough to produce the "food noise" reduction people talk about online.

A 2022 review by Rubino et al. in Obesity confirmed that appetite suppression and reduced caloric intake became statistically significant only after dose escalation was completed. So feeling nothing at week two on 0.25mg is not a product failure. It is how the drug is designed to work.

What did they get wrong (or right)?

She got the core mechanic right: 0.25mg is a starting dose, not an active dose, and expecting weight loss or appetite suppression at this stage is premature. That's accurate, and worth saying clearly because a lot of people abandon GLP-1 medications in the first month for exactly this reason.

Where she's slightly off is in framing the absence of side effects as suspicious. "I've spent 200 quid on a pen that's not doing anything for me" suggests she expects some signal of activity. But the absence of nausea, fatigue, or gastrointestinal symptoms at 0.25mg is also entirely normal, and arguably a good sign for tolerability at higher doses. The STEP programme's safety data showed side effect frequency correlates directly with dose level.

Her point about needing to cut caffeine, alcohol, and processed food is solid practical advice, not a replacement for medication but a genuine factor in GLP-1 efficacy. Davies et al. (2021, Lancet Diabetes and Endocrinology) found that lifestyle intervention combined with semaglutide produced better outcomes than medication alone.

What should you actually know?

If you're in the first four weeks of Wegovy and feeling nothing, that is expected. The 0.25mg phase exists to reduce the likelihood of nausea and vomiting when you escalate. It is not meant to produce weight loss. Stopping because you feel no effect at this stage is one of the most common reasons people don't give the medication a fair trial.

The dose escalation schedule for semaglutide typically runs from 0.25mg to 0.5mg to 1mg to 1.7mg before reaching 2.4mg, usually over 16 to 20 weeks. Real-world prescribing sometimes moves more slowly depending on individual tolerability. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed that participants who completed the full escalation and stayed on 2.4mg for two years lost an average of 15.2% of body weight.

One more thing worth addressing: she mentions being pre-diabetic and pushes back on commenters conflating Wegovy with Ozempic. She's right that Wegovy is licensed for weight management, and Ozempic (same molecule, different licensed dose) is licensed for type 2 diabetes. They are not interchangeable prescriptions. That's a real regulatory and clinical distinction, not just a brand preference.

Should her mental health concerns change anything?

This deserves a direct answer. She mentions her mental health has been suffering and frames weight loss as something that would help. That may well be true, and the connection between obesity and depression is well-documented (Luppino et al., 2010, Archives of General Psychiatry found a bidirectional relationship). But it also means she should be supported by her prescriber, not just handed a pen. GLP-1 medications are not mood treatments. If mental health is actively suffering during treatment, that's a conversation to have with a clinician, not something to push through alone.